Novo Nordisk (NVO) is replacing Chief Executive Officer Lars Fruergaard Jorgensen amid increased competition for its Wegovy obesity shots. The move follows a 53% decline in its share price over the past 12 months that has sliced more than $300 billion off its market value. Madison Muller reports on Bloomberg Television.

Bloomberg videos, provided by MT Newswires